In previous studies, several predictors of the efficacy of treatment with CGRP monoclonal antibodies have been identified, such as younger age (7), normal weight, unilateral pain, good response to triptan (18), comorbid hypertension, specific allelic variants in calcitonin receptor-like receptor (19) and unilateral cranial autonomic symptoms (20). The gene discussed is CALCRL; the disease is hypertensive disorder.